

Volume 28 (Supplement 2) May 2001



THE CANADIAN JOURNAL OF

Neurological Sciences

LE JOURNAL CANADIEN DES

Sciences Neurologiques

AN INTERNATIONAL JOURNAL / UN JOURNAL INTERNATIONAL

36th MEETING OF THE
CANADIAN CONGRESS OF
NEUROLOGICAL SCIENCES

ABSTRACTS



The official Journal of: The Canadian Neurological Society, The Canadian Neurosurgical Society,
The Canadian Society of Clinical Neurophysiologists, The Canadian Association of Child Neurology



Vincent Van Gogh




Joan of Arc

**YESTERDAY, PEOPLE WITH EPILEPSY
HAD TO BE EXTRAORDINARY TO SUCCEED.**



Sir Isaac Newton



Charles Dickens

EFFICACY ACROSS A BROAD RANGE OF SEIZURES.

- TOPAMAX demonstrates efficacy in Partial Onset, Primary Generalized Tonic-Clonic, and Lennox-Gastaut Seizures¹
- Desirable seizure-free results were shown in both Adults (19%)¹ and Children (22%)¹ with Partial Onset Seizures^{2,3}

NO EVIDENCE OF LIFE-THREATENING SIDE EFFECTS.

- Like most antiepileptics, the most common side effects are CNS related, usually mild to moderate and transient^{5,1}

ADULT PATIENTS MAY EXPERIENCE WEIGHT LOSS.


- 73% of patients (n=52) showed a mean weight decrease of 5.97 lb (Interim analysis. Average duration 60 days)⁴
- 96% of children in clinical trials (≥ one year) who lost weight showed resumption of weight gain in test period^{5,1}

TODAY, THERE'S TOPAMAX.

B.I.D. DOSING WITH THE PATIENT IN MIND.

- TOPAMAX is initiated and titrated to clinical response regardless of existing anticonvulsant therapy
- Tablets available on formulary^{††}

**NOW AVAILABLE
IN SPRINKLE
CAPSULES**



TOPAMAX*
topiramate

**NOW INDICATED
FOR CHILDREN**

HELPING PATIENTS MAKE MORE OF THEIR LIVES.

**TOPAMAX* topiramate Tablets and Sprinkle Capsules: indicated as adjunctive therapy for the management of patients (adults and children two years and older) with epilepsy who are not satisfactorily controlled with conventional therapy. There is limited information on the use of topiramate in monotherapy at this time.*

[†] Open label, 20 week trial (n=450 Adults). Optimal dosing was 300-350 mg/day (Average 288 mg/day).

[‡] Open label trial for children (n=72) treated for ≥ 3 months. Average dose of 10 mg/kg/day.

[§] CNS adverse events: Somnolence (30.1%), dizziness (28.3%), ataxia (21.2%), speech disorders (16.8%), psychomotor slowing (16.8%), nystagmus (15.0%), paresthesia (15.0%), nervousness (15.9%), difficulty with concentration/attention (8.0%), confusion (9.7%), depression (8.0%), anorexia (5.3%), language problems (6.2%) and mood problems (3.5%). In an audit of 1446 adults and 303 children, there appeared to be a similar pattern of adverse events.

^{**} The long-term effects of weight loss in pediatric patients are not known.

^{††} Limited use benefit: Ontario, Nova Scotia, New Brunswick, PEI. Full benefit: Quebec, Saskatchewan, British Columbia, Alberta, Manitoba.

Please refer to the TOPAMAX Prescribing Information for complete prescribing details.

REFERENCES: 1. TOPAMAX* topiramate Tablets and Sprinkle Capsules Product Monograph, May 11, 1999. 2. Kamin M, Kraut L, Olson W. Dose optimization of topiramate as add-on therapy in adults with treatment-resistant partial-onset seizures *Neurology* 1999;52 (Suppl 2):A525-526. 3. Glauser TA, Etterman R, Wyllie E et al. Open label topiramate in paediatric partial epilepsy *Epilepsia* 1997;38 (Suppl 3):94. 4. Rosenfeld WE et al. Topiramate and concomitant weight loss. *Epilepsia* 1997;38 (Suppl 8):98.

Neurology / neurosurgery physician or resident?

If so, you should become a member of one of these:

- Canadian Neurological Society
- Canadian Neurosurgical Society
- Canadian Society of Clinical Neurophysiologists
- Canadian Association of Child Neurologists



*M*EMBERSHIP BENEFITS

- Annual Membership Directory
- The Canadian Journal of Neurological Sciences
- Newsletters and Communications
- Manpower Information
- Education Opportunities
- Professional Development Initiatives
- Information and Services through the Secretariat
- Advocacy

*F*URTHER INFORMATION

For further information, or to join one of the CCNS societies, please call the secretariat office or complete the form on the website www.ccns.org.

Courier Address: 709 - 7015 Macleod Trail SW, Calgary, AB, T2H 2K6 Canada

Postal Address: P.O. Box 5456, Station A, Calgary, AB, T2H 1X8 Canada

Tel: (403) 229-9544; Fax: (403) 229-1661; E-mail: brains@ccns.org; Web: www.ccns.org